Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pulmatrix Inc    PULM

PULMATRIX INC (PULM)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2018 02/15/2018 02/16/2018 02/20/2018 02/21/2018 Date
1.41(c) 1.53(c) 1.48(c) 1.46(c) 1.48(c) Last
487 927 956 453 327 970 129 534 139 029 Volume
-2.76% +8.51% -3.27% -1.35% +1.37% Change
More quotes
Company
Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs.It designs and develops inhaled therapeutic... 
More about the company
Latest news on PULMATRIX INC
02/12PULMATRIX : Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole..
PR
02/12PULMATRIX, INC. (NASDAQ : PULM) Files An 8-K Regulation FD Disclosure
AQ
02/09PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
01/24PULMATRIX : Will Present Pulmazole Preclinical Data at the 8th Advances Against ..
PR
01/22PULMATRIX : Announces Acceptance of a Clinical Trial Application in Europe for P..
PR
01/17PULMATRIX, INC. (NASDAQ : PULM) Files An 8-K Regulation FD Disclosure
AQ
01/17PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2017PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2017PULMATRIX : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
2017PULMATRIX, INC. : Results of Operations and Financial Condition, Financial State..
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/15Nigeria needs return to 1963 parliamentary constitution-Clarke, SAN - By Abdu..
3
02/13Pulmatrix $PULM Now Covered by HC Wainwright  
02/13Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazol.. 
02/12BRIEF-Pulmatrix Announces First Subject Dosed In Phase 1 Clinical Trial Of Pu.. 
02/12Despite a big sell-off, analysts still have 8 analyst stock picks under $10 t..
1
More tweets
Qtime:76
News from SeekingAlpha
02/09Premarket analyst action - healthcare 
01/26Midday Gainers / Losers (1/26/2018) 
01/26Pulmatrix adds to up move, shares ahead 18% 
01/26Key events next week - healthcare 
2017Pulmatrix reports Q3 results 
Chart PULMATRIX INC
Duration : Period :
Pulmatrix Inc Technical Analysis Chart | PULM | US74584P1030 | 4-Traders
Technical analysis trends PULMATRIX INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Managers
NameTitle
Robert W. Clarke President, Chief Executive Officer & Director
Mark T. Iwicki Chairman
William E. Duke Chief Financial Officer, Treasurer & Secretary
David L. Hava Chief Scientific Officer
James M. Roach Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PULMATRIX INC3.55%31
GILEAD SCIENCES14.21%105 702
VERTEX PHARMACEUTICALS4.94%40 647
REGENERON PHARMACEUTICALS-12.04%35 686
BIOVERATIV INC91.99%11 211
GENMAB4.28%10 637